CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will
present at the Stifel 2018 Healthcare Conference in New York, NY on
Tuesday, November 13th at 9:30 a.m. ET.
A live audio webcast of the presentation will be available under the
“Investors and Media” section of Seres’ website. A replay will become
available approximately one hour after the event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the state of bacterial diversity and
function is imbalanced. Seres’ lead program, SER-109, has obtained
Breakthrough Therapy and Orphan Drug designations from the U.S. Food and
Drug Administration and is in Phase 3 development for multiply recurrent
C. difficile infection. SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate ulcerative colitis. Seres is
developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C. difficile
infection. Seres is also advancing SER-401 to augment the efficacy of
immuno-oncology treatment. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005022/en/
Source: Seres Therapeutics, Inc.
Carlo Tanzi, Ph.D., 617-203-3467
President, Investor Relations and Corporate Communications